Type I pityriasis rubra pilaris: Upregulation of tumor necrosis factor α and response to adalimumab therapy

Journal of Cutaneous Medicine and Surgery

Volumn 14, Issue 4, 2010, Pages 185-188

  Zhang, Yao Hua ^a   Zhou, Youwen ^a   Ball, Nigel ^a   Su, Ming Wan ^a   Xu, Jin Hua ^a   Zheng, Zhi Zhong ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BETAMETHASONE VALERATE; CALCIPOTRIOL; ISOTRETINOIN; MESSENGER RNA; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE REPORT; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; LOADING DRUG DOSE; PAPULE; PARAKERATOSIS; PHOTOTHERAPY; PITYRIASIS RUBRA PILARIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REMISSION; SKIN BIOPSY; SKIN EXAMINATION; UPREGULATION;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; PITYRIASIS RUBRA PILARIS; RECURRENCE; RETREATMENT; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 77955462690     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2010.09023     Document Type: Article

References (27)

1. Liao W, Mutasim D. Infliximab for the treatment of adult-onset pityriasis rubra pilaris. Arch Dermatol 2005;141:423-5.
2. Manoharan S, White S, Gumparthy K. Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab. Australas J Dermatol 2006;47:124-9.
3. Ruiz-Genao D, Lopez-Estebaranz J, Naz-Villalba E, et al. Pityriasis rubra pilaris successfully treated with infliximab. Acta Derm Venereol 2007;87:552-3.
4. Müller H, Gattringer C, Zelger B, et al. Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. J Am Acad Dermatol 2008;59 (5 Suppl):S65-70.
5. Ruzzetti M, Saraceno R, Carboni I, et al. Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab. J Eur Acad Dermatol Venereol 2008;22:117-8.
6. Barth D, Harth W, Treudler R, et al. Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate. J Dtsch Dermatol Ges 2009 Aug 18. [Epub ahead of print]
7. Seckin D, Tula E, Ergun T. Successful use of etanercept in type I pityriasis rubra pilaris. Br J Dermatol 2008;158:642-4.
8. Cox V, Lesesky E, Garcia B, et al. Treatment of juvenile pityriasis rubra pilaris with etanercept. J Am Acad Dermatol 2008;59 (5 Suppl):S113-4.
9. Davis K, Wu J, Murase J, et al. Clinical improvement of pityriasis rubra pilaris with combination etanercept and acitretin therapy. Arch Dermatol 2007;143:1597-9.
10. Griffiths W. Pityriasis rubra pilaris. Clin Exp Dermatol 1980;5:105-12.
11. Gonzalez-Lopez A, Velasco E, Pozo T, et al. HIV-associated pityriasis rubra pilaris responsive to triple antiretroviral therapy. Br J Dermatol 1999;140:931-4.
12. Albert M, Mackool B. Pityriasis rubra pilaris. Int J Dermatol 1999;38:1-11.
13. Daniela BG, Thomas R. Pityriasis rubra pilaris. In: Wolff K, Goldsmith L, Katz SI, et al, editors. Fitzpatrick's dermatology in general medicine. 7th ed. New York: McGraw-Hill; 2008. p. 232-6.
14. Walling HW, Swick BL. Pityriasis rubra pilaris responding rapidly to adalimumab. Arch Dermatol 2009;145:99-101.
15. Drosou A, Kirsner R, Welsh E, et al. Use of infliximab, an antitumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg 2003;7:382-6.
16. Keystone E, Haraoui B. Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin North Am 2004;30:349-64, vii.
17. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, et al. Adalimumab for treating rheumatoid arthritis. J Rheumatol 2006;33:1075-81.
18. de Vries M, van der Horst-Bruinsma I, Wolbink G. Adalimumab in juvenile rheumatoid arthritis. N Engl J Med 2008;359:2496.
19. Sfriso P, Ravaioli F. Adalimumab in juvenile rheumatoid arthritis. N Engl J Med 2008;359:2495.
20. Taddio A, Marchetti F. Adalimumab in juvenile rheumatoid arthritis. N Engl J Med 2008;359:2495-6.
21. Chew A, Bennett A, Smith C, et al. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol 2004;151:492-6.
22. Genovese M, Mease P, Thomson G, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34:1040-50.
23. Mease P, Ory P, Sharp J, et al. Adalimumab for long-term treatment of psoriatic arthritis: two-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9.
24. Gordon K, Langley R, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and openlabel extension study. J Am Acad Dermatol 2006;55:598-606.
25. Sladden M, Mortimer N, Hutchinson P. Extensive plaque psoriasis ? successfully treated with adalimumab (Humira). Br J Dermatol 2005;152:1091-2.
26. Larregue M, Champion R, Bressieux JM, et al. Acute pityriasis rubra pilaris in the child. Ann Dermatol Venereol 1983;110:221.
27. Betlloch I, Ramon R, Silvestre JF, et al. Acute juvenile pityriasis rubra pilaris: a superantigen mediated disease. Pediatr Dermatol 2001;18:411.